Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kyntra Bio (KYNB) Other Accumulated Expenses (2016 - 2018)

Historic Other Accumulated Expenses for Kyntra Bio (KYNB) over the last 5 years, with Q4 2018 value amounting to $5.5 million.

  • Kyntra Bio's Other Accumulated Expenses fell 1426.14% to $5.5 million in Q4 2018 from the same period last year, while for Dec 2018 it was $5.5 million, marking a year-over-year decrease of 1426.14%. This contributed to the annual value of $5.5 million for FY2018, which is 1426.14% down from last year.
  • Kyntra Bio's Other Accumulated Expenses amounted to $5.5 million in Q4 2018, which was down 1426.14% from $9.6 million recorded in Q3 2018.
  • Over the past 5 years, Kyntra Bio's Other Accumulated Expenses peaked at $10.3 million during Q3 2017, and registered a low of $3.2 million during Q2 2015.
  • Moreover, its 5-year median value for Other Accumulated Expenses was $5.6 million (2014), whereas its average is $6.2 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first crashed by 1432.17% in 2015, then surged by 8346.14% in 2017.
  • Over the past 5 years, Kyntra Bio's Other Accumulated Expenses (Quarter) stood at $5.6 million in 2014, then dropped by 14.32% to $4.8 million in 2015, then increased by 14.01% to $5.4 million in 2016, then increased by 18.95% to $6.5 million in 2017, then decreased by 14.26% to $5.5 million in 2018.
  • Its last three reported values are $5.5 million in Q4 2018, $9.6 million for Q3 2018, and $8.8 million during Q2 2018.